The Robotic Revolution in Surgery:

How Intelligent Machines Are Reshaping Global Healthcare

From prostate cancer operations to heart surgery and lung biopsies, robotic-assisted surgery is moving rapidly into the mainstream. But behind the futuristic machines lies a more complicated story of cost, access, evidence and the changing role of the surgeon.

By AI TV INFO | Global Intelligence — Health & Technology Unit

The operating room is changing.

For decades, minimally invasive surgery meant surgeons working through small incisions with long, rigid instruments and a two-dimensional camera view. Today, an increasing number of surgeons are sitting at sophisticated consoles, controlling articulated instruments capable of movements that conventional laparoscopic tools cannot easily reproduce.

This is robotic-assisted surgery (RAS)—and it is becoming an increasingly important part of modern healthcare.

The scale of the transformation is already substantial. More than 20 million patients worldwide had undergone procedures using Intuitive’s da Vinci systems by the end of 2025, according to the company. More than 3.1 million da Vinci procedures were performed during 2025 alone.

But robotic surgery is no longer synonymous with a single machine or manufacturer. Competitors including Medtronic, Stryker, Johnson & Johnson, CMR Surgical and manufacturers in Asia are building platforms designed to compete in an increasingly crowded market.

A market measured in billions

The commercial momentum is considerable.

One 2026 market analysis estimates that the global surgical robotic systems market was worth approximately $14.1 billion in 2025, rising to $17.2 billion in 2026 and potentially reaching $45.6 billion by 2033, representing a projected compound annual growth rate of 14.9%. Grand View Research estimates North America accounted for 47% of global revenue in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Different market-research firms produce different estimates because they define “robotic surgery” differently. Some include systems, instruments, accessories and services; others include broader categories of surgical robotics.

That distinction matters.

Market revenue is not the same thing as the number of robotic operations performed.

For that reason, procedure volume, installed systems, hospital penetration and manufacturer revenue should be treated as separate measures when assessing the industry’s real-world growth.

More than three million procedures—and rising

Intuitive reported approximately 3.153 million da Vinci procedures in 2025, compared with approximately 2.683 million in 2024—an increase of roughly 18%. The company expects worldwide da Vinci procedure growth of approximately 13% to 15% in 2026.

At the end of 2025, the company reported 11,106 da Vinci systems installed worldwide, up from 9,902 a year earlier.

That installed base is only one part of the global robotics landscape. Other manufacturers operate competing systems, meaning there is no single authoritative worldwide registry of every robotic-assisted operation.

Still, the numbers from the market leader demonstrate the direction of travel: robotic surgery is moving from early adoption toward large-scale clinical deployment.

North America remains the heavyweight

North America continues to dominate the commercial landscape.

According to Grand View Research, North America represented approximately 47% of the surgical robotic systems market in 2025. The United States also has the world’s largest installed base of da Vinci systems.

The reasons are familiar: high healthcare expenditure, substantial hospital investment capacity, established minimally invasive surgery programs, specialist training and a large market for high-value medical technology.

But the next phase of growth may be increasingly international.

Europe prepares for a robotic expansion

Europe is becoming an important second center of adoption.

The United Kingdom provides a striking example. NHS England announced plans in 2025 to expand robot-assisted operations from approximately 70,000 procedures in 2023/24 to 500,000 procedures annually by 2035. The NHS also projects that nine out of ten keyhole operations could eventually be performed with robotic assistance.

The scale of that ambition is significant.

If achieved, robotic assistance would no longer be an exceptional technology within Britain’s public health system. It would become part of the routine infrastructure of surgical care.

Asia becomes the next major battleground

Asia-Pacific is expected to be the fastest-growing major regional market.

The region combines rapidly expanding healthcare infrastructure, large patient populations and increasing demand for minimally invasive procedures. It is also becoming a manufacturing center for surgical robotics.

China is particularly important. Domestic companies are developing systems intended to compete on technology and price, potentially challenging the historical dominance of Western platforms.

This could have consequences beyond competition between manufacturers.

Lower-cost robotic platforms could eventually make the technology accessible to hospitals that cannot justify the capital expenditure associated with premium systems today.

What can a surgical robot actually do?

Despite the futuristic appearance, today’s mainstream surgical robots generally do not operate autonomously.

The surgeon remains in control.

The system translates the surgeon’s hand movements into precise movements of robotic instruments inside the patient. Depending on the platform, surgeons can benefit from high-definition three-dimensional visualization, articulated instruments, motion scaling and tremor filtering.

That can be particularly valuable in anatomically confined spaces.

Robotic-assisted surgery is now used across a wide range of specialties, including:

• Urology — particularly prostate and kidney surgery
• Gynecology — including hysterectomy and complex pelvic procedures
• General surgery — including hernia and abdominal operations
• Colorectal surgery
• Thoracic surgery
• Cardiac surgery
• Head and neck surgery
• Liver and pancreatic surgery
• Pediatric surgery
• Orthopedics
• Spine surgery
• Robotic bronchoscopy and lung biopsy

The technology is therefore expanding beyond the traditional image of a robot performing an operation through several abdominal ports.

Robotics is also moving into diagnosis

One of the most important developments is the expansion of robotic technology beyond surgical cutting and suturing.

Intuitive’s Ion platform, for example, is designed for minimally invasive lung biopsy and navigation. The company reported approximately 144,100 Ion procedures in 2025, up from 95,500 in 2024.

The trend illustrates a broader transformation: robotics is becoming a platform for navigation, diagnosis, intervention and data collection, not simply mechanical assistance during an operation.

Does robotic surgery produce better outcomes?

This is where the story becomes more complicated.

The marketing image of robotic surgery can suggest that the technology automatically produces superior outcomes. Scientific evidence does not support such a universal conclusion.

A large systematic review of randomized trials comparing robotic and laparoscopic abdominal and pelvic surgery found no statistically significant differences in several major outcomes across the studies, including mortality, postoperative complications, length of stay, conversion to open surgery and quality of life.

Robotic surgery can nevertheless offer important technical advantages in selected procedures.

Three-dimensional visualization, articulated instruments and improved ergonomics may help surgeons perform complex minimally invasive operations in difficult anatomical locations.

In other words:

The robot is a tool—not a guarantee of a better outcome.

The value of the technology depends on the procedure, the surgeon, the hospital, patient selection and the clinical pathway surrounding the operation.

The price of precision

Robotic surgery also comes with a substantial economic question.

Hospitals must consider not only the purchase price of a robotic system, but also:

• maintenance;
• specialized instruments;
• disposable components;
• operating-room infrastructure;
• staff training;
• surgeon training;
• software and technology upgrades;
• operating time.

That means the economic equation is complicated.

A robotic operation may be more expensive than an equivalent laparoscopic procedure, but the calculation can change if it reduces complications, shortens hospitalization or allows a hospital to perform more procedures efficiently.

The key question for healthcare systems is therefore not simply:

“Does the robot cost more?”

It is:

“Does the complete care pathway deliver enough clinical and operational value to justify the investment?”

A new business model for medical technology

The economics of robotic surgery also create an attractive recurring-revenue model for manufacturers.

The robot itself represents only part of the commercial ecosystem.

Instruments, accessories, service contracts, software and other recurring purchases can generate revenue long after a hospital has acquired the initial system.

Grand View Research estimates that surgical robotic accessories represented approximately 53.6% of market revenue in 2025 within its market definition.

That makes the robotic operating room resemble a technology platform: the initial machine establishes the installed base, while recurring instruments, accessories, services and software support the continuing commercial relationship.

The next frontier: AI

The most consequential change may not be another robotic arm.

It may be artificial intelligence.

More than 20 million da Vinci procedures have generated a vast body of real-world surgical data. Intuitive says researchers are already developing AI systems designed to understand surgical video, clinical reasoning, risk assessment and next-step planning.

The long-term vision is not necessarily a robot replacing the surgeon.

Instead, AI could become a new layer of assistance—helping with:

visual recognition → surgical planning → decision support → workflow optimization → performance analysis → training.

That could transform the operating room from a purely mechanical environment into a highly data-driven clinical system.

But autonomous complex surgery remains a fundamentally different proposition. Today’s mainstream robotic systems remain surgeon-controlled.

A technology race with a healthcare question at its center

The global robotic-surgery race is therefore about more than machines.

It is about who gets access to advanced surgery, how hospitals allocate capital, how surgeons are trained, how outcomes are measured and whether technological sophistication translates into meaningful improvements for patients.

The numbers suggest the transition is already well underway.

More than 20 million patients have undergone da Vinci procedures. More than 3.1 million da Vinci procedures were performed in 2025. The installed da Vinci base exceeded 11,000 systems, while market forecasts point toward a global surgical-robotics industry worth tens of billions of dollars within the next decade.

And governments are beginning to plan around that growth. In England alone, the NHS aims to increase robot-assisted procedures to 500,000 annually by 2035.

The question is no longer whether robotic technology belongs in the modern operating room.

Increasingly, the question is how far it will go—and who will benefit from it.

For AI TV INFO, that may be the most important story of all: the convergence of medicine, robotics and artificial intelligence is transforming surgery from a manual craft into an increasingly connected technological discipline.

The surgeon remains at the controls. But the operating room of the future is already taking shape.

Sources and data checked against Intuitive Surgical corporate reporting, NHS England and Grand View Research. Market-size figures are estimates and vary according to market definitions.